Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT00061646
- Lead Sponsor
- Abbott
- Brief Summary
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Progression free survival One year
- Secondary Outcome Measures
Name Time Method Overall survival One year Response rate One year
Trial Locations
- Locations (4)
Oncology-Hematology Group of South Florida
πΊπΈMiami, Florida, United States
University of Chicago
πΊπΈChicago, Illinois, United States
The West Cancer Clinic
πΊπΈMemphis, Tennessee, United States
University of Wisconsin
πΊπΈMadison,, Wisconsin, United States
Oncology-Hematology Group of South FloridaπΊπΈMiami, Florida, United States